Maddi Hebebrand, MC, Associate Editor

In the pivotal trials, dupilumab significantly reduced itch severity and urticaria activity at week 24 and increased rates of well-controlled disease and complete response compared with placebo.

Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.

A systematic review of 8 studies finds early evidence for microneedling plus exosome therapy across alopecia, aging, pigmentation, and scarring, but calls for larger trials.

Weekly microneedling combined with daily topical 5% minoxidil produced statistically significant hair density gains in 40 women with female pattern hair loss.

The deal would vault the combined company to 7th-largest biosimilar player globally, with direct implications for biologic access in dermatology.

Combination therapy may be particularly beneficial for frontal hairline regrowth, a traditionally difficult area to treat.

Interim phase 2a data show ORKA-001, a half-life extended IL-23 inhibitor, achieved complete skin clearance in 63.5% of patients at week 16.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

In the Chair puts you in the hot spot, challenging you to navigate complex, real-world cases.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

Early clinical trials indicate that dual- and triple-target antibodies may provide faster onset and more consistent itch relief in moderate to severe AD.

Affecting up to 25% of children worldwide, pediatric AD carries a significant quality of life burden that extends to caregivers.

The biologic is the first of its kind approved for young children with antihistamine-refractory CSU, expanding an existing indication that previously covered adults and adolescents.

Clinicians agreed that itch — not lesion count or BSA alone — is the most clinically meaningful driver of treatment escalation in patients with atopic dermatitis.

Patients frequently experience persistent symptoms, visible lesions, and recurrent flares that affect daily functioning and self-image.

Most AD referrals were low urgency, contributing to prolonged wait times exceeding 30 weeks on average.

A meta-analysis cited in the review found depression prevalence among melasma patients at 43.4% — approximately 12 times the estimated global rate — highlighting the psychiatric weight of pregnancy-associated skin changes.

The study represents a repurposing strategy, using dupilumab as a tool compound to probe whether immune-targeted therapy can address a biologically defined subgroup of MDD.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

In the Chair puts you in the hot spot, challenging you to navigate complex, real-world cases.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

The episode highlights how clinicians integrate new therapies through mentorship, peer discussion, and real-world clinical experience.

The CHECK-US study found that patients commonly perceive their CHE as driven by overlapping environmental, biological, psychological, and lifestyle factors.

A new case-control study found that patients with pemphigus vulgaris and bullous pemphigoid face more than twice the odds of comorbid acute stress disorder compared with matched controls.

Elevated rates of herpes simplex, herpes zoster, and opportunistic infections in the vitiligo cohort underscore infection risk considerations

A large All of Us cohort analysis found high rates of obesity and depression in both eczema and psoriasis, reinforcing their systemic nature.

Many participants in the mobile screening program have never previously seen a dermatologist.

Oral therapies may provide more widespread and effective repigmentation, especially in extensive nonsegmental vitiligo.

Work productivity loss fell from 44.3% at baseline to 19.0% at week 52 in the total study population, representing a clinically meaningful reduction in occupational impairment over the full treatment period.

Two oral BTK inhibitors and two injectable biologics demonstrated superior efficacy over placebo in a systematic review of 16 CSU trials.